 | | Vol. 15.16 – 28 April, 2021 |
| |
|
|
| The authors reasoned that the expansion of new neuronal types occurred in a stepwise manner analogous to animal speciation, and they explored this by defining transcriptomic relationships using a top-down approach.
[Science] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists investigated the role of chaperone-mediated autophagy, a selective autophagy shown to degrade neurodegeneration-related proteins, in neuronal proteostasis.
[Cell] |
|
|
|
| Using direct conversion of Alzheimer’s disease patient fibroblasts into induced neurons, investigators generated an age-equivalent neuronal model.
[Cell Stem Cell] |
|
|
|
| The authors characterized the cellular properties and in vivo tissue repair activity of glial enriched progenitor cells differentiated from human-induced pluripotent stem cells.
[Science Translational Medicine] |
|
|
|
| Scientists employed auxin-inducible degradation to deplete Polycomb repressive complex 2 holocomplex 1 (PRC2.1) subunit MTF2 or PRC2.2 subunit JARID2 during differentiation of embryonic stem cells to neural progenitors.
[Molecular Cell] |
|
|
|
| Induced pluripotent stem cells derived from individuals deficient in CDKL5 protein were used to generate neural cells. Proteomic and phosphoproteomic approaches revealed disruption of several pathways, including microtubule-based processes and cytoskeleton organization.
[Molecular Psychiatry] |
|
|
|
| Researchers report the astrocyte-derived secreted lipocalin Glial Lazarillo, a homolog of human Apolipoprotein D, and its neuronal receptor, the brain-specific short isoforms of Drosophila lipophorin receptor 1, cooperatively mediated neuron-glia lipid shuttling and support dendrite morphogenesis.
[Nature Communications] |
|
|
|
| Investigators demonstrated that mouse microglia exhibited temperature-dependent movement in vitro and in vivo that was mediated by TRPV4 channels within the physiological range of body temperature.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Scientists showed that in mouse hippocampal neurons, dense core vesicles fusion was strongly and equally reduced in synaptotagmin-1 (Syt1)- or Syt7-deficient neurons, but combined Syt1/Syt7 deficiency did not reduce fusion further.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Researchers explored the therapeutic potential of targeting mitochondrial translation and report the results of high-content screening with putative blockers of mitochondrial ribosomes.
[Cell Reports] |
|
|
|
| To identify therapeutic targets in MYC-amplified medulloblastoma, investigators employed a CRISPR-Cas9 essentiality screen targeting 1,140 genes. They identified CDK7 as a mediator of medulloblastoma tumorigenesis.
[Cell Reports] |
|
|
|
| Researchers showed that leukemia inhibitory factor protein was abundantly expressed in Schwann cells after rat sciatic nerve injury.
[Cell Death & Disease] |
|
|
|
|
| The unique ability of extracellular vesicles (EVs) to pass through the blood-brain barrier further conferred them an important role in the bidirectional communication between the central nervous system and periphery, and the application of EVs enabled the diagnosis, prognosis, and therapy of neuroinflammatory diseases in a minimally invasive manner.
[Molecular Therapy] |
|
|
|
| New models of posterior embryo development identify neuromesodermal progenitors as a major bifurcation point in generating the spinal cord and somites and are leading to the production of cell types with the full range of axial identities critical for the repair of trunk and spine disorders. This is coupled with organoid technologies including assembloids, circuitoids, and gastruloids.
[Frontiers in Cellular Neuroscience] |
|
|
|
|
| The Allen Institute and BioMarin Pharmaceutical, Inc. announced a collaboration that will use technologies developed at the Allen Institute to create new gene therapies aimed at rare genetic diseases of the central nervous system.
[BioMarin Pharmaceutical, Inc.] |
|
|
|
| Revive Therapeutics Ltd. announced it has filed an application with the FDA to receive Orphan Drug Designation for Psilocybin to treat moderate to severe traumatic brain injury.
[Revive Therapeutics Ltd.] |
|
|
|
| Voyager Therapeutics, Inc. announced the FDA has removed its clinical hold on the company’s Investigational New Drug (IND) application for VY-HTT01, a gene therapy candidate for the treatment of Huntington’s disease, and confirmed that the company may proceed with its planned Phase I/II clinical trial.
[Voyager Therapeutics, Inc.] |
|
|
|
|
|
|
|
| | Karolinska Institutet – Stockholm, Sweden |
|
|
|
| | Deep Genomics, Inc. – Toronto, Ontario, Canada |
|
|
|
| | Cyprus Cancer Research Institute – Republic of Cyprus |
|
|
|
| | Max Planck Institute – Nijmegen, Netherlands |
|
|
|
| | University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
